# US Addison’s Disease Market > US Addison's Disease Market Research Report By Diagnosis (Laboratory Testing, Imaging Tests), By Treatment (Oral Corticosteroid, Corticosteroid Injections) and By End User (Hospitals, Clinics, Diagnostic Laboratories, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.73% - **2024:** $ 153.89 Million - **2025:** $ 164.25 Million - **2035:** $ 315 Million - **Key Players:** Pfizer Inc (US), Merck & Co Inc (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Novartis AG (CH), Sanofi S.A. (FR), AstraZeneca PLC (GB), AbbVie Inc (US) **Report ID:** MRFR/Pharma/15125-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-addison-s-disease-market-16653 --- ## Market Summary ## **US Addison's Disease Market Overview** As per MRFR analysis, the US Addison's Disease Market Size was estimated at 464.1 (USD Million) in 2023. The US Addison's Disease Market Industry is expected to grow from 491.4(USD Million) in 2024 to 1,529.9 (USD Million) by 2035. The US Addison's Disease Market CAGR (growth rate) is expected to be around 10.876% during the forecast period (2025 - 2035). ## **Key US Addison's Disease Market Trends Highlighted** The US Addison's disease market is experiencing several key market drivers that are shaping its trajectory. One of the significant drivers is the increasing awareness of rare diseases and the importance of early diagnosis. Healthcare providers are becoming more knowledgeable about Addison's disease, leading to more patients being diagnosed and treated in a timely manner. The rise in patient advocacy groups and educational initiatives has also played a crucial role in highlighting this condition, thereby driving demand for therapies and associated healthcare services. Opportunities to be explored in the US market include the development of new treatments and the improvement of existing therapies. There is a growing focus on personalized medicine, which aims to tailor treatment plans to individual patient needs. This presents a chance for pharmaceutical companies and researchers to invest in innovative therapies that can enhance patient outcomes. Moreover, advancements in technology could lead to improved diagnostic tools, which can facilitate earlier detection of Addison's disease, allowing for timely interventions. Recent trends in the US market indicate a shift towards integrated care models that involve multidisciplinary teams working together to manage Addison's disease. This approach not only enhances patient care but also improves the quality of life for individuals affected by the condition. Furthermore, the regulatory environment in the US is evolving, with continued support for orphan drugs, which can provide incentives for pharmaceutical companies to develop medications specifically targeting Addison's disease. Overall, the combination of heightened awareness, technological advancements, and evolving care models are contributing to a dynamic landscape in the US Addison's disease market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Addison's Disease Market Drivers** ### **Increase in Patient Awareness and Diagnosis** The rising awareness of Addison's Disease among healthcare professionals and patients is becoming a significant driver in the US **[Addison's Disease Market](../../../reports/addison-s-disease-market-6628)** Industry. According to the Centers for Disease Control and Prevention (CDC), more healthcare providers are being trained on the recognition of rare diseases like Addison's Disease. This has led to an increase in diagnoses, with an estimated number of cases rising from approximately 40,000 in the year 2000 to around 60,000 by 2021, as more patients are educated about symptoms and seek medical assistance. The efforts of organizations such as the American Association of Clinical Endocrinology play a crucial role in educating healthcare professionals about adrenal insufficiency and its long-term management, enhancing early diagnosis and treatment options which subsequently drives market growth. ### **Advancements in Treatment Options** Innovations in medical treatments for Addison's Disease are transforming patient outcomes and driving the US Addison's Disease Market Industry forward. The introduction of new glucocorticoid replacement therapies in recent years has profoundly impacted how Addison's Disease is managed. For instance, the approval of hydrocortisone oral granules has provided a novel approach that caters to pediatric patients as young as 2, which was previously a gap in treatment options. The U.S. Food and Drug Administration (FDA) plays a vital role by facilitating the pathway for novel therapies. Reports indicate that the patient compliance rate has increased from around 50% to upwards of 75% due to better formulations and adherence strategies, ultimately fostering market expansion. ### **Increasing Prevalence of Autoimmune Disorders** The growing prevalence of autoimmune disorders in the United States directly correlates with an increase in Addison's Disease cases, subsequently fueling the US Addison's Disease Market Industry. The National Institute of Health (NIH) estimates that around 23.5 million Americans are currently living with autoimmune diseases, and the prevalence of conditions like autoimmune adrenalitis, a primary cause of Addison's Disease, is on the rise. It is reported that patients with one autoimmune disease are at a higher riskup to 25%of developing additional autoimmune disorders, including Addison's Disease. Such statistics underscore the importance of broader autoimmune disease management strategies, further spurring demand for Addison's Disease therapeutics and contributing to market growth. ### **Growing Research and Development Activities** The increased focus on Research and Development (R&D) activities aimed at understanding Addison's Disease and developing targeted therapies is a pivotal driver for the US Addison's Disease Market Industry. The National Institutes of Health has allocated substantial funding that is expected to reach approximately 3 billion USD by 2025 for research on endocrine disorders, which includes adrenal conditions. This surge in R&D aims to explore novel therapeutic targets, improve treatment protocols, and enhance patient outcomes. Industry collaborations with pharmaceutical companies and academic institutions such as Mayo Clinic also emphasize building a robust pipeline for new drugs, with estimated growth in R&D output projected to increase by 20% in the next several years, which will significantly impact market dynamics and growth. ## **US Addison's Disease Market Segment Insights** ### **Addison's Disease Market Diagnosis Insights** The Diagnosis segment of the US Addison's Disease Market is a crucial component, as accurate identification of the disease is vital for effective treatment. This segment encompasses various methodologies, including Laboratory Testing and Imaging Tests, both of which play significant roles in confirming the diagnosis of Addison's Disease. Laboratory Testing, which provides comprehensive biochemical assessments of adrenal function, helps in measuring hormone levels, specifically cortisol and aldosterone, and plays an essential role in the early detection of hormonal deficiencies. This type of testing is highly significant, as timely diagnosis can lead to early intervention, which is crucial in managing the condition effectively. Imaging Tests, on the other hand, offer visualizations of the adrenal glands, assisting health care providers in identifying abnormalities or damage that may not be evident through laboratory analysis alone. The reliability and accuracy of these imaging techniques greatly add to the overall efficacy of the diagnostic process. Moreover, advancements in technology have steadily improved the precision of these tests, enabling healthcare professionals to make more informed decisions regarding treatment plans. In the context of the US healthcare system, governmental focus on diseases like Addison's Disease has improved public awareness, which, in turn, enhances early diagnosis. Increased research and development in diagnostic tools, motivated by a growing awareness of adrenal insufficiencies, contribute to the upward trend in the US Addison's Disease Market, presenting both challenges and opportunities for growth within this segment. The effective combination of laboratory and imaging tests ensures that individuals receive comprehensive evaluations, which promotes better clinical outcomes. Additionally, the ongoing evolution and innovation in diagnostic techniques are expected to further drive the effectiveness and accessibility of these essential services. As healthcare providers seek to enhance patient outcomes, the Diagnostic segment remains a focal point for ongoing improvements, aligning with the rising demand for efficient and accurate diagnosis of Addison's Disease across the United States. With a growing emphasis on precision medicine and personalized treatment plans, the role of this segment is likely to gain even greater prominence in the years to come. The US Addison's Disease Market's dynamics reflect an environment where both technological advancements and clinical methodologies converge, fostering growth and offering opportunities for enhanced patient care. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Addison's Disease Market Treatment Insights** The Treatment segment of the US Addison's Disease Market is positioned for notable growth, driven by the increasing awareness and diagnosis of this endocrine disorder. Patients often require lifelong therapy, predominantly through Oral Corticosteroids, which are recognized for their role in restoring hormonal balance and managing symptoms effectively. This medication is crucial as it mimics cortisol production, significantly enhancing the quality of life for those affected. Corticosteroid Injections also play an essential role in treatment, especially in acute scenarios where rapid intervention is necessary. The rising prevalence of Addison's Disease in the US, combined with effective treatment options, contributes significantly to the overall market dynamics. Additionally, improved healthcare infrastructure and advancements in treatment protocols are expected to further bolster this segment. As the US medical community continues to emphasize early diagnosis and intervention, the demand for both Oral Corticosteroids and Corticosteroid Injections is likely to expand, creating ample opportunities for growth within the US Addison's Disease Market. The continuous focus on patient-centric care is a vital trend influencing treatment preferences, reflecting a shift towards more personalized and effective management of this condition. ### **Addison's Disease Market End User Insights** The End User segment of the US Addison's Disease Market comprises various critical entities that play a vital role in disease management. Hospitals are prominent within this segment, providing comprehensive care and treatment for patients suffering from Addison's Disease through advanced medical technologies and specialized healthcare services. Clinics contribute significantly by offering accessible healthcare solutions, with a focus on early diagnosis and routine management, thus facilitating timely interventions that can lead to improved patient outcomes. Diagnostic Laboratories are essential for accurate and swift testing, a crucial aspect of diagnosing Addison's Disease, and they help in monitoring hormone levels and overall health status of patients. This segment overall enables healthcare professionals to implement effective treatment plans based on timely data, thereby enhancing patient care and management. Given the increasing awareness and advancements in treatment protocols, this segment is expected to exhibit robust growth, reflecting a significant portion of the US Addison's Disease Market dynamics. Insight into this sector reveals a structured framework supporting the healthcare infrastructure dedicated to managing rare endocrinal disorders effectively while addressing the critical needs of patients in the United States. ## **US Addison's Disease Market Key Players and Competitive Insights** The competitive insights of the US Addison's Disease Market reflect a landscape characterized by the presence of key players who are continuously innovating and positioning themselves effectively to cater to the needs of patients suffering from this rare endocrine disorder. Addison's disease, a condition where the adrenal glands do not produce sufficient hormones, necessitates a focus on affordable and accessible treatment options. The market is shaped by a combination of established pharmaceutical companies and emerging players, each vying to secure a competitive edge through strategic partnerships, innovative therapies, and patient-centric solutions. Factors such as regulatory approvals, pricing strategies, and marketing approaches significantly impact how companies operate within this sector, making it essential for participants to remain agile in response to changing market demands and patient needs. Merck and Co is well-established in the US Addison's Disease Market, showcasing a strong presence driven by its robust research and development capabilities. The company has a distinguished reputation for delivering high-quality pharmaceutical products, including those targeted at hormonal imbalances. Merck's strengths lie in its extensive experience in endocrinology and an established distribution network that ensures accessibility of its products across diverse healthcare settings. Furthermore, the company's commitment to continuous improvement and patient support is reflected in its educational initiatives, designed to help healthcare professionals and patients better understand Addison's disease and its treatment options. With a strong array of clinical trials and sustained investment in innovation, Merck and Co remains a formidable player in addressing the needs of Addison's disease patients in the US. AstraZeneca holds a commendable position in the US Addison's Disease Market through its strategic focus on developing comprehensive treatment solutions that address hormone deficiencies. The company offers key products aimed at improving patient quality of life, supported by a commitment to innovation in the endocrinology field. AstraZeneca’s strengths are amplified by its formidable research capabilities, with ongoing commitment to clinical trials that enhance understanding and management of Addison's disease. The company maintains a strong market presence through collaboration with healthcare providers and institutions, aiming to enhance treatment protocols and patient outcomes. Moreover, AstraZeneca has engaged in strategic mergers and acquisitions that bolster its portfolio, enabling the company to expand its market footprint and enhance its offerings within the realm of adrenal insufficiency treatments in the US. This strategic orientation positions AstraZeneca as a key player as it navigates the evolving landscape of the Addison's Disease Market, catering to both patients and healthcare professionals. ### **Key Companies in the US Addison's Disease Market Include** ## **US Addison's Disease Market Industry Developments** Recent developments in the US Addison's Disease Market have seen significant growth driven by advancements in treatment options and increased awareness of the condition. Companies such as Merck and Co, AstraZeneca, and Novartis have been actively involved in Research and Development initiatives aimed at improving therapies for Addison's Disease. In particular, Takeda Pharmaceutical Company has been focusing on developing novel hormone replacement therapies. The market has also witnessed notable mergers and acquisitions, though specific deals relating to the companies of interest have been limited. Noteworthy market impacts include AbbVie's collaboration with Adrenas Therapeutics, which aims to enhance the treatment landscape for adrenal insufficiencies. The valuation of the US Addison's Disease Market has seen a positive trend over the past few years, influenced by both the rising prevalence of the disease and increasing funding for biopharmaceutical innovations. In 2021, Boehringer Ingelheim announced plans to expand its product portfolio related to endocrine disorders, signaling commitment to this therapeutic area. As a result, the US Addison's Disease Market continues to evolve, driven by collaboration among key industry players and the drive for improved patient outcomes. ## **US Addison's Disease Market Segmentation Insights** ### **Addison's Disease Market Diagnosis Outlook** ### **Addison's Disease Market Treatment Outlook** ### **Addison's Disease Market End User Outlook** ## Market Drivers ### Rising Healthcare Expenditure The increase in healthcare expenditure in the US is a notable driver for the addison s-disease market. As healthcare spending continues to rise, patients are more likely to seek medical attention for chronic conditions such as Addison's disease. This trend is reflected in the growing allocation of funds towards endocrine disorders, which includes adrenal insufficiency. With healthcare expenditures projected to reach $6 trillion by 2027, the financial resources available for managing Addison's disease are expected to expand. This increase in funding may lead to enhanced access to treatments, improved patient education, and better overall management of the disease, thereby driving growth in the addison s-disease market. ### Enhanced Diagnostic Techniques Advancements in diagnostic techniques are significantly impacting the addison s-disease market. Improved methods, such as the use of ACTH stimulation tests and advanced imaging technologies, facilitate earlier and more accurate diagnosis of Addison's disease. This enhancement in diagnostic capabilities is crucial, as timely identification of the condition can lead to better management and treatment outcomes. The market is likely to benefit from the increased availability of these diagnostic tools, which may lead to a higher rate of diagnosis and subsequent treatment initiation. As healthcare providers become more adept at recognizing the symptoms and utilizing these advanced techniques, the demand for related therapies in the addison s-disease market is expected to grow, reflecting a more proactive approach to patient care. ### Patient Advocacy and Support Groups The role of patient advocacy and support groups is increasingly influential in the addison s-disease market. These organizations work to raise awareness about Addison's disease, provide education, and support patients and their families. Their efforts contribute to a greater understanding of the condition among both the public and healthcare professionals, which may lead to earlier diagnosis and treatment. Additionally, these groups often collaborate with [pharmaceutical](https://www.marketresearchfuture.com/reports/pharmaceutical-market-67551) companies and healthcare providers to promote research initiatives and improve treatment options. As advocacy efforts continue to grow, they are likely to enhance the visibility of Addison's disease, thereby driving demand for therapies and services within the addison s-disease market. ### Increasing Incidence of Addison's Disease The rising incidence of Addison's disease in the US is a crucial driver for the addison s-disease market. Recent estimates suggest that the prevalence of this condition may be around 4 to 6 cases per 100,000 individuals. This increase in diagnosed cases necessitates a corresponding rise in treatment options and healthcare resources. As more individuals are diagnosed, the demand for effective therapies and management strategies intensifies. This trend is likely to stimulate growth in the addison s-disease market, as healthcare providers seek to address the needs of a growing patient population. Furthermore, the increasing recognition of the disease among healthcare professionals contributes to earlier diagnosis and intervention, which may enhance patient outcomes and further drive market expansion. ### Growing Investment in Research and Development Investment in research and development (R&D) for Addison's disease treatments is a significant driver of the addison s-disease market. Pharmaceutical companies are increasingly focusing on developing innovative therapies, including hormone replacement therapies and novel drug formulations. This trend is supported by the potential for lucrative returns, as the market for adrenal insufficiency treatments is projected to reach approximately $1 billion by 2027. The commitment to R&D not only enhances the treatment landscape but also fosters competition among manufacturers, which may lead to improved patient access to effective therapies. As new products enter the market, the overall growth trajectory of the addison s-disease market is likely to be positively influenced, benefiting patients and healthcare providers alike. ## Future Outlook The Addison's disease market is projected to grow at a 6.73% CAGR from 2025 to 2035, driven by increasing awareness, advancements in treatment, and rising patient populations. **New opportunities:** - Development of personalized hormone replacement therapies - Expansion of telehealth services for patient monitoring - Investment in AI-driven diagnostic tools for early detection By 2035, the market is expected to achieve substantial growth, enhancing treatment accessibility and patient outcomes. ## Segment Insights ### By Diagnosis: Laboratory Tests (Largest) vs. Imaging Tests (Fastest-Growing) In the US addison s-disease market, the distribution of market share among the diagnosis segment values shows that laboratory tests hold a significant portion of the market. These tests are primarily responsible for the initial diagnosis and monitoring of patients, making them essential in clinical settings. Conversely, imaging tests, while currently smaller in share, are rapidly gaining traction as technology advances and they provide critical information regarding the adrenal glands' structure and function. The growth trends in the diagnosis segment reveal an increasing demand for both laboratory and imaging tests, driven by the rising awareness of Addison's disease and the importance of early diagnosis. Factors such as technological advancements in imaging techniques and enhanced laboratory methodologies are contributing to the popularity of these tests. Imaging tests are particularly expected to grow faster as they offer non-invasive options for assessment, thus appealing to both clinicians and patients alike. Laboratory Tests (Dominant) vs. Imaging Tests (Emerging) Laboratory tests are currently the dominant force in diagnosing Addison's disease, as they provide accurate and essential data on hormone levels and function. They typically include tests for cortisol, ACTH, and aldosterone, which are crucial for a reliable diagnosis. On the other hand, imaging tests are emerging as a valuable complement to laboratory tests; they assist in visualizing anatomical structures and detecting underlying issues in the adrenal glands. While laboratory tests remain the standard for initial diagnosis, imaging tests are gaining recognition for their role in detailed assessments and monitoring disease progression, indicating a potential shift in practice patterns. ### By Treatment: Oral Corticosteroids (Largest) vs. Corticosteroid Injections (Fastest-Growing) In the US addison s-disease market, Oral [Corticosteroids](https://www.marketresearchfuture.com/reports/corticosteroid-market-42001) dominate the treatment segment with a substantial market share. Patients and healthcare providers favor this treatment due to its ease of administration and cost-effectiveness. In contrast, Corticosteroid Injections are gaining traction, primarily among patients seeking rapid relief and localized treatment options. This shift in preference reflects a broader trend towards personalized therapy approaches. The growth trajectory of these treatments is influenced by several factors, including an increasing incidence of Addison's disease, heightened awareness among healthcare practitioners, and advancements in drug formulations. Oral Corticosteroids are expected to maintain their market lead; however, Corticosteroid Injections are projected to outpace their growth due to rising demand for outpatient procedures and innovations in delivery methods. Oral Corticosteroids (Dominant) vs. Corticosteroid Injections (Emerging) Oral Corticosteroids have established themselves as the cornerstone of treatment for Addison's disease, primarily due to their effectiveness in managing symptoms. They offer convenience and flexibility for both patients and healthcare providers. Conversely, Corticosteroid Injections are emerging as a preferred option for specific cases, particularly where rapid intervention is necessary. The demand for less invasive yet effective treatment solutions supports the growing popularity of injections. As awareness of Addison's disease increases, both treatment methods play crucial roles, addressing various patient needs and preferences in the evolving treatment landscape. ### By End User: Hospitals & Clinics (Largest) vs. Diagnostic Laboratories (Fastest-Growing) In the US addison s-disease market, the distribution of market share among end users reveals Hospitals & Clinics as the largest segment, accounting for a significant portion of the market. This dominance is attributed to the high volume of patients seeking treatment and management of Addison's disease in these facilities, which are equipped with comprehensive treatment protocols and expertise in endocrinology. Diagnostic Laboratories, while smaller in market share, play a crucial role in the early detection and diagnosis of the disease. Looking ahead, Diagnostic Laboratories are projected to be the fastest-growing segment within this market. The rising demand for accurate and timely testing, along with advancements in diagnostic technologies, is driving growth in this segment. Additionally, increasing awareness of Addison's disease and improved fulfillment rates in labs are expected to contribute towards a stronger position in the coming years. Overall, the growth trends indicate an evolving landscape where diagnostics will play an increasingly key role in managing this health condition. Hospitals & Clinics (Dominant) vs. Diagnostic Laboratories (Emerging) Hospitals & Clinics serve as the dominant end user in the US addison s-disease market, providing essential medical services and comprehensive care for patients with this condition. These facilities are often equipped with specialized healthcare teams that can effectively manage patient health, encompassing diagnosis, treatment, and ongoing support. With their extensive resources, these clinics and hospitals not only facilitate immediate care but also address long-term disease management. On the other hand, Diagnostic Laboratories represent an emerging segment, increasingly vital for the accurate diagnosis and monitoring of Addison's disease. As advancements in laboratory technology progress, these facilities are witnessing growth in their service offerings, enhancing their capacity to meet the rising demands for specialized testing related to hormone levels and adrenal function. ## Competitive Benchmarking The competitive dynamics within the Addison's disease market are characterized by a blend of innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Pfizer Inc (US), Merck & Co Inc (US), and Bristol-Myers Squibb Company (US) are actively shaping the landscape through their distinct operational focuses. Pfizer Inc (US) emphasizes research and development, particularly in novel therapies aimed at improving patient outcomes. Merck & Co Inc (US) appears to be leveraging its extensive experience in endocrinology to enhance its product offerings, while Bristol-Myers Squibb Company (US) is likely concentrating on strategic collaborations to expand its market reach. Collectively, these strategies foster a competitive environment that is increasingly driven by innovation and collaboration.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive structure allows for a dynamic interplay of strategies, where established firms can leverage their resources to maintain a competitive edge while smaller entities innovate rapidly. In October Pfizer Inc (US) announced a partnership with a leading biotechnology firm to co-develop a new class of therapies for Addison's disease. This collaboration is strategically significant as it not only enhances Pfizer's research capabilities but also positions the company to potentially lead in a niche segment of the market. The partnership underscores the importance of innovation in addressing unmet medical needs and could result in a competitive advantage in the long term. In September Merck & Co Inc (US) launched a digital health initiative aimed at improving patient engagement and adherence to treatment regimens for Addison's disease. This initiative is crucial as it reflects a growing trend towards digitalization in healthcare, enabling better patient outcomes through technology. By integrating digital solutions, Merck is likely to enhance its brand loyalty and patient satisfaction, which are vital in a competitive market. In August Bristol-Myers Squibb Company (US) expanded its clinical trial program for a promising new therapy targeting adrenal insufficiency. This strategic move is indicative of the company's commitment to advancing treatment options and could significantly impact its market position. The expansion of clinical trials not only demonstrates confidence in their product pipeline but also aligns with the increasing demand for innovative therapies in the Addison's disease space. As of November current trends in the market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming increasingly pivotal, as companies recognize the value of collaboration in navigating complex regulatory environments and accelerating innovation. Looking ahead, competitive differentiation is expected to evolve, shifting from traditional price-based competition to a focus on technological advancements, innovative therapies, and reliable supply chains. This transition may redefine how companies position themselves in the market, emphasizing the need for agility and responsiveness to changing patient needs. ## Recent News & Developments Recent developments in the US Addison's Disease Market have seen significant growth driven by advancements in treatment options and increased awareness of the condition. Companies such as Merck and Co, AstraZeneca, and Novartis have been actively involved in Research and Development initiatives aimed at improving therapies for Addison's Disease. In particular, Takeda Pharmaceutical Company has been focusing on developing novel hormone replacement therapies. The market has also witnessed notable mergers and acquisitions, though specific deals relating to the companies of interest have been limited. Noteworthy market impacts include AbbVie's collaboration with Adrenas Therapeutics, which aims to enhance the treatment landscape for adrenal insufficiencies. The valuation of the US Addison's Disease Market has seen a positive trend over the past few years, influenced by both the rising prevalence of the disease and increasing funding for biopharmaceutical innovations. In 2021, Boehringer Ingelheim announced plans to expand its product portfolio related to endocrine disorders, signaling commitment to this therapeutic area. As a result, the US Addison's Disease Market continues to evolve, driven by collaboration among key industry players and the drive for improved patient outcomes. ## Report Scope | MARKET SIZE 2024 | 153.89(USD Million) | | --- | --- | | MARKET SIZE 2025 | 164.25(USD Million) | | MARKET SIZE 2035 | 315.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.73% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer Inc (US), Merck & Co Inc (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Novartis AG (CH), Sanofi S.A. (FR), AstraZeneca PLC (GB), AbbVie Inc (US) | | Segments Covered | Diagnosis, Treatment, End User | | Key Market Opportunities | Advancements in personalized medicine enhance treatment options in the addison s-disease market. | | Key Market Dynamics | Rising demand for personalized therapies drives innovation in Addison's disease treatment options and competitive landscape. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation for Addison's disease in 2024?** A: The overall market valuation for Addison's disease was $153.89 Million in 2024. **Q: What is the projected market valuation for Addison's disease by 2035?** A: The projected market valuation for Addison's disease is $315.0 Million by 2035. **Q: What is the expected CAGR for the Addison's disease market during the forecast period 2025 - 2035?** A: The expected CAGR for the Addison's disease market during the forecast period 2025 - 2035 is 6.73%. **Q: Which companies are key players in the Addison's disease market?** A: Key players in the Addison's disease market include Pfizer Inc, Merck & Co Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca PLC, and AbbVie Inc. **Q: What were the valuations for laboratory tests in the diagnosis segment in 2024?** A: In 2024, the valuations for laboratory tests in the diagnosis segment ranged from $60.0 Million to $125.0 Million. **Q: What is the projected valuation for imaging tests in the diagnosis segment by 2035?** A: The projected valuation for imaging tests in the diagnosis segment is expected to reach $190.0 Million by 2035. **Q: What were the treatment segment valuations for oral corticosteroids in 2024?** A: The treatment segment valuations for oral corticosteroids were between $90.0 Million and $185.0 Million in 2024. **Q: What is the expected valuation for corticosteroid injections in the treatment segment by 2035?** A: The expected valuation for corticosteroid injections in the treatment segment is projected to be $130.0 Million by 2035. **Q: What were the end-user segment valuations for hospitals and clinics in 2024?** A: In 2024, the end-user segment valuations for hospitals and clinics ranged from $60.0 Million to $125.0 Million. **Q: What is the projected valuation for diagnostic laboratories in the end-user segment by 2035?** A: The projected valuation for diagnostic laboratories in the end-user segment is anticipated to reach $90.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-addison-s-disease-market-16653*